In this on-demand webinar Intertek experts Danika Martyn, Kirt Phipps and Nigel Baldwin discusses the latest requirements for successful submissions to EFSA. In particular we provide:

  • an update on the requirements for exposure data;
  • an overview of the “Benchmark Dose” and its increasing practical application in defining safety endpoints, rather than the No observable adverse effect level;
  • an update on how EFSA is practically applying the latest guidance on nanomaterials and its decision trees; and,
  • a brief update on the latest Commission proposal for transparency in risk assessment and what this may mean for future applicants.